We are live on ! Find out more
HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

Delisted

HZNP was delisted on the 5th of October, 2023.

354 hedge funds and large institutions have $10.5B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2020 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 97 increasing their positions, 133 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 37

122% more call options, than puts

Call options by funds: $48.1M | Put options by funds: $21.7M

100% more capital invested

Capital invested by funds: $5.24B → $10.5B (+$5.23B)

35% more funds holding in top 10

Funds holding in top 10: 1723 (+6)

20% more funds holding

Funds holding: 295354 (+59)

27% less repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 133

Holders
354
Holders Change
+59
Holders Change %
+20%
% of All Funds
7.26%
Holding in Top 10
23
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+35.29%
% of All Funds
0.47%
New
97
Increased
97
Reduced
133
Closed
37
Calls
$48.1M
Puts
$21.7M
Net Calls
+$26.4M
Net Calls Change
+$23.9M
Name Holding Trade Value Shares
Change
Change in
Stake
IHAM
126
Integral Health Asset Management
New York
$4.45M +$3.42M +80,000 New
HIM
127
Hillsdale Investment Management
Ontario, Canada
$4.39M -$2.04M -47,700 -38%
JGUA
128
John G. Ullman & Associates
New York
$4.27M -$8.56K -200 -0.3%
Two Sigma Investments
129
Two Sigma Investments
New York
$4.21M +$3.24M +75,687 New
FAM
130
Fred Alger Management
New York
$4.16M +$2.77M +64,836 +648%
FP
131
Foundry Partners
Minnesota
$3.92M -$116K -2,706 -4%
PAM
132
Panagora Asset Management
Massachusetts
$3.91M -$1.93M -45,005 -39%
GIP
133
Granite Investment Partners
California
$3.7M +$86.5K +2,021 +3%
Natixis Advisors
134
Natixis Advisors
Massachusetts
$3.63M +$2.79M +65,261 New
AG
135
Aperio Group
California
$3.58M -$263K -6,136 -9%
Stifel Financial
136
Stifel Financial
Missouri
$3.15M -$481K -11,244 -17%
Balyasny Asset Management
137
Balyasny Asset Management
Illinois
$3.09M -$17.6M -411,656 -88%
Assenagon Asset Management
138
Assenagon Asset Management
Luxembourg
$3.05M +$2.35M +54,899 New
ECM
139
ExodusPoint Capital Management
New York
$2.96M +$2.28M +53,315 New
NIP
140
Nicholas Investment Partners
California
$2.86M -$4.72M -110,285 -68%
Los Angeles Capital Management
141
Los Angeles Capital Management
California
$2.85M +$1.39M +32,454 +173%
JAM
142
JW Asset Management
Florida
$2.82M
VRS
143
Virginia Retirement Systems
Virginia
$2.81M -$55.6K -1,300 -3%
Zurich Cantonal Bank
144
Zurich Cantonal Bank
Switzerland
$2.8M +$218K +5,089 +11%
US Bancorp
145
US Bancorp
Minnesota
$2.79M +$573K +13,397 +36%
DIM
146
Delta Investment Management
California
$2.74M +$2.11M +49,288 New
KeyBank National Association
147
KeyBank National Association
Ohio
$2.7M +$993K +23,201 +91%
CAM
148
ClariVest Asset Management
California
$2.65M -$2.01M -46,892 -50%
Treasurer of the State of North Carolina
149
Treasurer of the State of North Carolina
North Carolina
$2.6M -$250K -5,840 -8%
TD Asset Management
150
TD Asset Management
Ontario, Canada
$2.57M +$1.97M +46,163 New

HZNP Hedge Fund Activity: Q2 2020 in Review

354 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2020, worth a combined $10.5B — up 100% from $5.24B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new HZNP positions and 37 closed out — a net gain of 60 holders — while 97 added to existing stakes and 133 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $139M. The largest seller was Deerfield Management, cutting an estimated $168M.

  • 354 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2020, up from 295 in Q1 2020.
  • Funds reported $10.5B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2020, up 100% quarter-over-quarter.
  • 97 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2020 and 37 closed out, a net change of +60 holders.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2020 was Adage Capital Partners, an estimated $139M added.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2020 was Deerfield Management, an estimated $168M sold.

Based on aggregated 13F filings for Q2 2020.